Durect Corp. CEO James Brown told BioWorld Today that, although phase Ib results proved encouraging with the endogenous, oral small-molecule DUR-928 in patients with nonalcoholic steatohepatitis (NASH), the phase II trial planned for next year will test the drug in acute kidney damage, an indication where today “the only thing they can do is give you fluids and pray.”